Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Expected to Rise, HC Wainwright Analyst Says

Unicycive Therapeutics (NASDAQ:UNCY) had its target price upped by HC Wainwright from $4.00 to $7.50 in a research note issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Unicycive Therapeutics Stock Down 6.4 %

NASDAQ:UNCY opened at $0.57 on Tuesday. Unicycive Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.60. The company has a fifty day moving average of $0.59 and a 200-day moving average of $0.57. The firm has a market capitalization of $59.67 million, a P/E ratio of -0.59 and a beta of 2.26.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.13). On average, analysts anticipate that Unicycive Therapeutics will post -0.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Unicycive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new position in shares of Unicycive Therapeutics in the 3rd quarter worth $29,000. Virtu Financial LLC raised its holdings in Unicycive Therapeutics by 566.8% during the third quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock worth $30,000 after buying an additional 62,881 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Unicycive Therapeutics by 142.4% in the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company’s stock valued at $46,000 after buying an additional 34,183 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Unicycive Therapeutics by 30.3% during the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company’s stock valued at $417,000 after buying an additional 122,089 shares during the last quarter. Finally, Acuta Capital Partners LLC increased its position in shares of Unicycive Therapeutics by 16.4% during the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company’s stock worth $1,829,000 after acquiring an additional 323,801 shares in the last quarter. Institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.